Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.
Steven P. Treon, MD, PhD
Advertisement
Articles by Steven P. Treon, MD, PhD
Advertisement
Latest Updated Articles
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström MacroglobulinemiaPublished: July 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5